Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 70
Filter
1.
Mol Cell Proteomics ; 20: 100059, 2021.
Article in English | MEDLINE | ID: mdl-33109704

ABSTRACT

Antibodies play essential roles in both diagnostics and therapeutics. Epitope mapping is essential to understand how an antibody works and to protect intellectual property. Given the millions of antibodies for which epitope information is lacking, there is a need for high-throughput epitope mapping. To address this, we developed a strategy, Antibody binding epitope Mapping (AbMap), by combining a phage displayed peptide library with next-generation sequencing. Using AbMap, profiles of the peptides bound by 202 antibodies were determined in a single test, and linear epitopes were identified for >50% of the antibodies. Using spike protein (S1 and S2)-enriched antibodies from the convalescent serum of one COVID-19 patient as the input, both linear and potentially conformational epitopes of spike protein specific antibodies were identified. We defined peptide-binding profile of an antibody as the binding capacity (BiC). Conceptually, the BiC could serve as a systematic and functional descriptor of any antibody. Requiring at least one order of magnitude less time and money to map linear epitopes than traditional technologies, AbMap allows for high-throughput epitope mapping and creates many possibilities.


Subject(s)
COVID-19/immunology , Epitope Mapping/methods , Spike Glycoprotein, Coronavirus/immunology , Antibodies, Monoclonal/immunology , Antibodies, Monoclonal/metabolism , Antibodies, Viral/metabolism , Enzyme-Linked Immunosorbent Assay , Epitopes/metabolism , Escherichia coli Proteins/immunology , High-Throughput Nucleotide Sequencing , Humans , Immune Sera/blood , Immune Sera/immunology , Peptide Library
2.
ACS Comb Sci ; 22(11): 656-666, 2020 11 09.
Article in English | MEDLINE | ID: mdl-33063508

ABSTRACT

Dysregulation of IFN-α is the basis for pathogenesis of autoimmune as well as infectious diseases. Identifying inflammatory signatures in peripheral blood of patients is an approach for monitoring active infection. Hence, estimation of type I IFNs as an inflammatory biomarker to scrutinize disease status after treatment is useful. Accordingly, an Aptamer Linked Immobilized Sorbent Assay (ALISA) for the detection of IFN-α in serum samples was developed. Sixteen aptamers were screened for their ability to bind IFN-α. Aptamer IFNα-3 exhibited specificity for IFN-α with no cross-reactivity with interferons ß and γ and human serum albumin. The disassociation constant (Kd) was determined to be 3.96 ± 0.36 nM, and the limit of detection was ∼2 ng. The characterized IFNα-3 aptamer was used in ALISA to screen tuberculosis (TB) patients' sera. An elevated IFN-α level in sera derived from untreated TB patients (median = 0.31), compared to nontuberculous household contacts (median = 0.13) and healthy volunteers (median = 0.12), and further a decline in IFN-α level among treated patients (median = 0.13) were seen. The ALISA assay facilitates direct estimation of inflammatory protein(s) in circulation unlike mRNA estimation by real time PCR. Designing of aptamers similar to the IFNα-3 aptamer provides a novel approach to assess other inflammatory protein(s) in patients before, during, and after completion of treatment and would denote clinical improvement in successfully treated patients.


Subject(s)
Aptamers, Nucleotide/chemistry , Interferon-alpha/blood , Tuberculosis/diagnosis , Bacterial Proteins/genetics , Bacterial Proteins/metabolism , Biological Assay , Biomarkers/blood , Biomarkers/metabolism , Enzyme-Linked Immunosorbent Assay , Humans , Immune Sera/blood , Immune Sera/metabolism , Limit of Detection , RNA, Messenger/metabolism , SELEX Aptamer Technique , Tuberculosis/genetics
3.
Pharmeur Bio Sci Notes ; 2020: 141-160, 2020.
Article in English | MEDLINE | ID: mdl-32788037

ABSTRACT

For acellular pertussis (aP) vaccines, the current European Pharmacopoeia (Ph. Eur.) monograph Pertussis vaccine (acellular, component, adsorbed) (1356) requires an immunogenicity assay in mice or guinea pigs to assess the potency of each lot of vaccine (Ph. Eur. general method 2.7.16. Assay of pertussis vaccine (acellular)). This biological assay, carried out on the final bulk of the vaccine lot, is based on the measurement of the specific antibody response to the 5 antigenic components (pertussis toxin (PT), Fimbrial haemagglutinin (FHA), pertactin (PRN) and Fimbriae 2 and 3 (FIM2/3)) that are present in the combined aP vaccines. In the mouse assay, serum antibody levels are measured by ELISA. The immunogenicity of a vaccine under test is estimated versus a homologous reference vaccine and a reference antiserum e.g. the first Ph. Eur. Biological Reference Preparation for Bordetella (B.) pertussis mouse anti-serum (BRP1), established in 1998, is used to normalise the titre of antibodies (expressed in ELISA Units (ELU)/mL). In anticipation of the depletion of BRP1 stocks, a project was launched in 2013 by the Biological Standardisation Programme (BSP) of the European Directorate for the Quality of Medicines & HealthCare (EDQM) in order to establish a new standardised reference serum. The project, referred to herein as BSP129, was conducted in 2 phases: 1) the production and characterisation of a mouse serum pool (using a multicomponent aP vaccine marketed in Canada similar to the vaccine used in the BRP1 production as immunogen) and of candidate BRP batches (cBRPs) and 2) an international collaborative study aimed at calibrating the cBRPs in terms of antibody levels against PT, FHA, PRN and FIM2/3. This article presents the design and results of the first phase of the collaborative study to establish the optimal conditions for immunisation and bleeding of mice in order to produce a large pool of hyper-immune serum against the 5 antigens. After the characterisation of this pool, cBRP pilot lots were manufactured by freeze-drying diluted solutions of the hyper-immune serum pool. The pilot lots were then characterised in two Official Medicines Control Laboratories (OMCLs) for their antibody contents against aP vaccine antigens using in-house ELISA (based on methods developed by 2 European vaccine manufacturers) and Multiplex Immunoassay (MIA) methods. The antibody titres recovered demonstrated that a dilution factor of 1/40 could be considered for the scaled-up manufacture of candidate reference preparations (cBRPs). Three batches (15 000 vials) of cBRP were manufactured and fully characterised. In light of the data obtained, and although titration results between the ELISA methods were sometimes discrepant, it was agreed that the establishment study (phase 2) could be launched. Real-time and accelerated stability studies were also included in the first study phase to document the stability of the cBRPs in freeze-dried form and after reconstitution and storage at -20°C±5°C. The results showed that the stability of the freeze-dried cBRPs at usual storage and shipment temperatures is acceptable and that reconstituted cBRP solutions are stable for 12 months at -20°C±5°C. It could therefore be recommended to freeze small aliquots of the 1 mL solution obtained by the reconstitution of one BRP vial in order to store them for use in separate assays. With the application of this strategy, the stocks of the BRP1 replacement batches should cover the needs of OMCLs and manufacturers for at least the next decade.


Subject(s)
Bordetella pertussis/drug effects , Immune Sera/drug effects , International Cooperation , Laboratories/standards , Pertussis Vaccine/standards , Pharmacopoeias as Topic/standards , Animals , Bordetella pertussis/immunology , Europe , Female , Immune Sera/blood , Immune Sera/immunology , Immunization/methods , Immunization/standards , Mice , Pertussis Vaccine/administration & dosage , Pertussis Vaccine/immunology , Reference Standards
4.
Pharmeur Bio Sci Notes ; 2020: 161-202, 2020.
Article in English | MEDLINE | ID: mdl-32788038

ABSTRACT

A project aimed at establishing replacement batches for the European Pharmacopoeia (Ph. Eur.) Biological Reference Preparation (BRP) Bordetella (B.) pertussis mouse antiserum was started in 2013 under the aegis of the Biological Standardisation Programme (BSP) of the European Directorate for the Quality of Medicines & HealthCare (EDQM). This BRP is used for the immunogenicity assay in mice to assess the potency of acellular pertussis (aP) vaccines as described in Ph. Eur. general method 2.7.16. Assay of pertussis vaccine (acellular). In a preliminary phase of the project (referred to herein as BSP129 phase 1) a hyper-immune serum pool was produced in mice using a combined aP vaccine as immunogen. This pool was used to generate 3 freeze-dried candidate (c) B. pertussis anti-mouse serum BRP batches (cBRP2, cBRP3 and cBRP4). After the pre-qualification that showed their suitability as candidate batches, an international collaborative study (BSP129 phase 2) was carried out in order to standardise these 3 batches against the current BRP1 in terms of anti-PT, -FHA, -PRN and -FIM2/3 antibody contents. For the sake of continuity with the standardisation of BRP1, the corresponding WHO standard (1RR 97/642) was introduced as a second reference for the calibration of the 3 candidate BRPs. Eleven laboratories took part in phase 2. Ten of them performed the ELISA method they use routinely for aP vaccine batch release and one laboratory performed the Multiplex Immunoassay (MIA) as an alternative test. Four participants titrated the antibodies against all 5 pertussis antigens, 5 participants determined the antibody content against 3 antigens (PT, FHA, PRN), one participant titrated the antibodies against PT and FHA antigens and one laboratory determined the antibody content for the PT antigen only. Details of all ELISA methods used were analysed to evaluate their impact on the calibration of the cBRPs. The variability of the results in relation to the nature and methodology of the tests appeared rather limited. Discrepant titres of cBRPs were measured depending on the reference used: the use of the 1RR induced an overestimation (in 8 out of 11 laboratories) and a large inter-laboratory variation in the calculated titres. Regardless of the reference used, equivalency between the calculated titres of cBRP2 and cBRP3 was observed, whilst cBRP4 had systematically lower titres for all antibodies against the 5 acellular pertussis vaccine components. Based on these observations, it was decided to establish the candidate BRP batches against BRP1 and to assign the following potencies based on the mean values determined through centrally calculated results of the calibration assays performed by ELISA in BSP129 phase 2: For cBRP2 and cBRP3 Anti-pertussis toxin: 37 ELISA Units (ELU) per vial Anti-filamentous haemagglutinin: 114 ELU per vial Anti-pertactin: 44 ELU per vial Anti-fimbrial agglutinogens (FIM2/3): 25 ELU per vial For cBRP4 Anti-pertussis toxin: 32 ELU per vial Anti-filamentous haemagglutinin: 98 ELU per vial Anti-pertactin 38 ELU per vial Anti-fimbrial agglutinogens (FIM2/3):23 ELU per vial In February 2018, BRP2, BRP3 and BRP4 were adopted by correspondence by the Ph. Eur. Commission.


Subject(s)
Bordetella pertussis/drug effects , International Cooperation , Laboratories/standards , Pertussis Vaccine/standards , Pharmacopoeias as Topic/standards , World Health Organization , Animals , Bordetella pertussis/immunology , Hemagglutinins/blood , Hemagglutinins/immunology , Immune Sera/blood , Immune Sera/immunology , Mice , Pertussis Toxin/blood , Pertussis Toxin/immunology , Pertussis Vaccine/administration & dosage , Reference Standards
5.
Pharmeur Bio Sci Notes ; 2020: 125-140, 2020.
Article in English | MEDLINE | ID: mdl-32677612

ABSTRACT

Equine influenza (EI) is an important respiratory disease of horses, with welfare and economic consequences. Vaccination remains one of the most efficient prevention methods available. Equine influenza virus (EIV) is constantly evolving and consequently EI vaccines need to be updated on a regular basis. In 2010, the World Organisation for Animal Health (OIE) Expert Surveillance Panel (ESP) on EI provided a new recommendation for EI vaccine strain composition, including the incorporation of representative EIV strains of both Florida Clade 1 and Clade 2 sub-lineages (FC1 and FC2, respectively). In this context, the European Pharmacopoeia (Ph. Eur.) - OIE reference panel for EI had to be complemented by an antiserum raised in horses against the FC2 representative EIV strain A/eq/Richmond/1/07. An international collaborative study was organised and managed by the European Directorate for the Quality of Medicines and HealthCare (EDQM) within the framework of its Biological Standardisation Programme (BSP). The study aimed at evaluating a new candidate reference for use as a common OIE International Standard/Ph. Eur. Biological Reference Preparation (BRP) horse antiserum to FC2 EIV A/equine/Richmond/1/07. The standard was to be established using the SRH and HI tests for subsequent use in immunogenicity, efficacy and batch potency assay of EI vaccines as a Ph. Eur. BRP (Ph. Eur. monograph 0249) and for use in clinical diagnostic tests as an OIE-approved International Standard Reagent (OIE chapter 3.5.7). The collaborative study confirmed the suitability of the candidate and an SRH titre was assigned. The candidate was adopted as a BRP by the Ph. Eur. Commission and approved by the OIE Biological Standards Commission as an International Standard Serum in November 2017 and February 2018, respectively.


Subject(s)
Immune Sera/blood , Influenza A Virus, H3N8 Subtype/isolation & purification , International Cooperation , Laboratories/standards , Pharmacopoeias as Topic/standards , Animals , Europe , Female , Horses , Immune Sera/genetics , Immune Sera/immunology , Influenza A Virus, H3N8 Subtype/genetics , Influenza A Virus, H3N8 Subtype/immunology , Phylogeny , Reference Standards , United States
6.
Med Microbiol Immunol ; 209(2): 177-188, 2020 Apr.
Article in English | MEDLINE | ID: mdl-32078028

ABSTRACT

Recently, Zika virus (ZIKV) has become more widespread, thus attracting global attention. The vaccine against Japanese encephalitis virus (JEV) is currently used in China, being included in planned immunisation regimes. Although ZIKV and JEV are closely related mosquito-borne Flaviviruses, and a complex cross-immune response within flaviviruses has been demonstrated, the effect of JEV vaccination on ZIKV infection has not been well described. Thus, this study aimed to explore the impact of different titres of anti-JEV antibodies (Abs) against ZIKV infection using sera from healthy human donors in Guangzhou and anti-JEV rabbit polyclonal antibodies (pAbs) in vitro and vivo. Human anti-JEV Ab titres were tested at decreasing concentrations as the age increased. A neutralising effect on ZIKV infection was observed when anti-JEV Ab titres in human sera or rabbit pAbs were high (the corresponding age was under 30 years). Even though a lower titre in human sera showed no apparent effect, whereas rabbit pAbs had an antibody-dependent enhancement(ADE)effect, we proved an ADE effect in vivo for the first time. This study suggests that individuals over 60 years of age are at high risk for JEV and ZIKV infection, and screening this age group for infection should strengthen. Furthermore, a deep exploration of the relationship between anti-JEV Abs and ZIKV infection is needed.


Subject(s)
Antibodies, Neutralizing/immunology , Antibodies, Viral/immunology , Encephalitis Virus, Japanese/immunology , Encephalitis, Japanese/immunology , Immune Sera/immunology , Zika Virus Infection/immunology , Zika Virus/immunology , Adolescent , Adult , Animals , Antibodies, Neutralizing/blood , Antibodies, Viral/blood , Antibody-Dependent Enhancement , Child , Child, Preschool , Chlorocebus aethiops , Cross Protection , Cross Reactions , Encephalitis, Japanese/prevention & control , Female , Humans , Immune Sera/administration & dosage , Immune Sera/blood , Infant , K562 Cells , Male , Mice, Inbred C57BL , Middle Aged , Neutralization Tests , Rabbits , Vaccination , Vero Cells , Young Adult
8.
Exp Parasitol ; 192: 19-24, 2018 Sep.
Article in English | MEDLINE | ID: mdl-30031120

ABSTRACT

Amoebae from the genus Acanthamoeba are facultative pathogens of humans and other animals. In humans they most frequently infect the eye causing a sight threatening infection known as Acanthamoeba keratitis (AK), and also cause an often fatal encephalitis (GAE). A mannose-binding protein (MBP) has been identified as being important for Acanthamoeba infection especially in AK. This lectin has previously been characterized from Acanthamoeba castellanii as consisting of multiple 130 kDa subunits. MBP expression correlates with pathogenic potential and is expressed in a number of Acanthamoeba species. Here we report the purification of a similar lectin from Acanthamoeba culbertsoni and the production of a monoclonal antibody to it. The A. culbertsoni MBP was isolated by affinity chromatography using α-D-mannose agarose and has an apparent molecular weight of 83 kDa. The monoclonal antibody is an IgM that is useful in both western blots and immunofluorescence. We expect that this antibody will be useful in the study of the pathology of A. culbertsoni and in its identification in clinical samples.


Subject(s)
Acanthamoeba/immunology , Antibodies, Monoclonal/biosynthesis , Antibodies, Protozoan/biosynthesis , Mannose-Binding Lectin/immunology , Protozoan Proteins/immunology , Acanthamoeba/chemistry , Acanthamoeba Keratitis/parasitology , Animals , Antigens, Protozoan/immunology , Blotting, Western , Electrophoresis, Polyacrylamide Gel , Enzyme-Linked Immunosorbent Assay , Hybridomas , Immune Sera/blood , Immunoglobulin Isotypes , Immunohistochemistry , Mice , Mice, Inbred BALB C
9.
Emerg Microbes Infect ; 7(1): 100, 2018 May 31.
Article in English | MEDLINE | ID: mdl-29855467

ABSTRACT

Highly pathogenic avian influenza (HPAI) A(H5N1) viruses pose a significant economic burden to the poultry industry worldwide and have pandemic potential. Poultry vaccination against HPAI A(H5N1) viruses has been an important component of HPAI control measures and has been performed in Vietnam since 2005. To systematically assess antigenic matching of current vaccines to circulating field variants, we produced a panel of chicken and ferret antisera raised against historical and contemporary Vietnamese reference viruses representing clade variants that were detected between 2001 and 2014. The antisera were used for hemagglutination inhibition (HI) assays to generate data sets for analysis by antigenic cartography, allowing for a direct comparison of results from chicken or ferret antisera. HI antigenic maps, developed with antisera from both hosts, revealed varying patterns of antigenic relationships and clustering of viruses that were dependent on the clade of viruses analyzed. Antigenic relationships between existing poultry vaccines and circulating field viruses were also aligned with in vivo protection profiles determined by previously reported vaccine challenge studies. Our results establish the feasibility and utility of HPAI A(H5N1) antigenic characterization using chicken antisera and support further experimental and modeling studies to investigate quantitative relationships between genetic variation, antigenic drift and correlates of poultry vaccine protection in vivo.


Subject(s)
Antigenic Variation , Hemagglutinin Glycoproteins, Influenza Virus/immunology , Immune Sera/immunology , Influenza A Virus, H5N1 Subtype/isolation & purification , Influenza in Birds/immunology , Animals , Antibodies, Viral/blood , Antibodies, Viral/immunology , Chick Embryo , Chickens/blood , Chickens/virology , Female , Ferrets/blood , Ferrets/virology , Hemagglutination Inhibition Tests , Hemagglutinin Glycoproteins, Influenza Virus/chemistry , Hemagglutinin Glycoproteins, Influenza Virus/genetics , Immune Sera/blood , Influenza A Virus, H5N1 Subtype/chemistry , Influenza A Virus, H5N1 Subtype/genetics , Influenza A Virus, H5N1 Subtype/immunology , Influenza in Birds/blood , Influenza in Birds/virology , Male , Phylogeny , Poultry Diseases/blood , Poultry Diseases/immunology , Poultry Diseases/virology , Species Specificity , Vietnam
10.
PLoS One ; 12(2): e0172163, 2017.
Article in English | MEDLINE | ID: mdl-28192483

ABSTRACT

Serum Bactericidal Activity (SBA) assay is the method of choice to evaluate the complement-mediated functional activity of both infection- and vaccine-induced antibodies. To perform a typical SBA assay, serial dilutions of sera are incubated with target bacterial strains and complement. The conventional SBA assay is based on plating on agar the SBA reaction mix and counting the surviving bacterial colony forming units (CFU) at each serum dilution. Even with automated colony counting, it is labor-intensive, time-consuming and not amenable for large-scale studies. Here, we have developed a luminescence-based SBA (L-SBA) method able to detect surviving bacteria by measuring their ATP. At the end of the SBA reaction, a single commercially available reagent is added to each well of the SBA plate, and the resulting luminescence signal is measured in a microplate reader. The signal obtained is proportional to the ATP present, which is directly proportional to the number of viable bacteria. Bactericidal activity is subsequently calculated. We demonstrated the applicability of L-SBA with multiple bacterial serovars, from 5 species: Citrobacter freundii, Salmonella enterica serovars Typhimurium and Enteritidis, Shigella flexneri serovars 2a and 3a, Shigella sonnei and Neisseria meningitidis. Serum bactericidal titers obtained by the luminescence readout method strongly correlate with the data obtained by the conventional agar plate-based assay, and the new assay is highly reproducible. L-SBA considerably shortens assay time, facilitates data acquisition and analysis and reduces the operator dependency, avoiding the plating and counting of CFUs. Our results demonstrate that L-SBA is a useful high-throughput bactericidal assay.


Subject(s)
Adenosine Triphosphate/immunology , Bacteria/immunology , Blood Bactericidal Activity/immunology , High-Throughput Screening Assays/methods , Immune Sera/immunology , Adenosine Triphosphate/metabolism , Animals , Bacteria/metabolism , Citrobacter freundii/immunology , Citrobacter freundii/metabolism , Immune Sera/blood , Linear Models , Mice , Microbial Viability/immunology , Neisseria meningitidis/immunology , Neisseria meningitidis/metabolism , Reproducibility of Results , Salmonella enterica/immunology , Salmonella enterica/metabolism , Shigella flexneri/immunology , Shigella flexneri/metabolism , Shigella sonnei/immunology , Shigella sonnei/metabolism , Species Specificity
11.
Methods Mol Biol ; 1161: 11-25, 2014.
Article in English | MEDLINE | ID: mdl-24899416

ABSTRACT

Hemagglutination-inhibition (HI) assay is a classical laboratory procedure for the classification or subtyping of hemagglutinating viruses. For influenza virus, HI assay is used to identify the hemagglutinin (HA) subtype of an unknown isolate or the HA subtype specificity of antibodies to influenza virus. Since the HI assay is quantitative it is frequently applied to evaluate the antigenic relationships between different influenza virus isolates of the same subtype. The basis of the HI test is inhibition of hemagglutination with subtype-specific antibodies. The HI assay is a relatively inexpensive procedure utilizing standard laboratory equipment, is less technical than molecular tests, and is easily completed within several hours. However when working with uncharacterized viruses or antibody subtypes the library of reference reagents required for identifying antigenically distinct influenza viruses and or antibody specificities from multiple lineages of a single hemagglutinin subtype requires extensive laboratory support for the production and optimization of reagents.


Subject(s)
Antibodies, Viral/blood , Antibodies, Viral/immunology , Hemagglutination Inhibition Tests/methods , Influenza A virus/classification , Influenza A virus/isolation & purification , Animals , Antibody Specificity , Antigens, Viral/immunology , Chickens/virology , Erythrocytes/virology , Hemagglutinin Glycoproteins, Influenza Virus/immunology , Immune Sera/blood , Immune Sera/immunology , Influenza A virus/immunology
12.
Methods Mol Biol ; 1161: 27-36, 2014.
Article in English | MEDLINE | ID: mdl-24899417

ABSTRACT

The neuraminidase-inhibition (NI) assay is a laboratory procedure for the identification of the neuraminidase (NA) glycoprotein subtype in influenza viruses or the NA subtype specificity of antibodies to influenza virus. A serological procedure for subtyping the NA glycoprotein is critical for the identification and classification of avian influenza (AI) viruses. The macroprocedure was first described in 1961 by Aminoff and was later modified to a microtiter plate procedure (micro-NI) by Van Deusen et al. (Avian Dis 27:745-750, 1983). The micro-NI procedure reduces the quantity of reagents required, permits the antigenic classification of many isolates simultaneously, and eliminates spectrophotometric interpretation of results. Although, the macro-NI has been shown to be more sensitive than the micro-NI, the micro-NI test is very suitable for testing sera for the presence of NA antibodies and has proven to be a practical and rapid method for virus classification. This chapter provides an overview of the USDA validated micro-NI procedure for the identification of subtype-specific NA in AIV and antibodies.


Subject(s)
Antibodies, Viral/immunology , Antibody Specificity , Influenza A virus/enzymology , Influenza A virus/immunology , Neuraminidase/antagonists & inhibitors , Neuraminidase/immunology , Animals , Antibodies, Viral/blood , Antigens, Viral/immunology , Chick Embryo , Immune Sera/blood , Immune Sera/immunology , Influenza A virus/classification
13.
J Immunoassay Immunochem ; 35(2): 173-82, 2014.
Article in English | MEDLINE | ID: mdl-24295180

ABSTRACT

The transcriptional factor plays an important role in the regulation of gene expression and crucial to understand the biology of organisms. Mycobacterium tuberculosis, the causative agent of tuberculosis, harbors multiple transcriptional factors. Few transcriptional factors are well-documented antigens. Based on the screening of antigen with TB patients sera, a functional unknown ORF (Rv2175c) annotated as transcriptional factor was heterologously expressed, purified and for serodiagnostic value. E.coli recombinant Rv2175c protein was produced and antibodies were generated in rabbit using the recombinant antigens. ELISA and novel electrochemical immunosensor were employed in a parallel fashion in order to define its serodiagnositic value. Electrochemical immunosensor showed a sharp difference between health and TB sera. The data showed that Rv2715c is antigenic and can be used for TB seradignosis candidate in non BCG vaccinated areas.


Subject(s)
Antibodies, Bacterial/immunology , Immune Sera/blood , Immune Sera/immunology , Mycobacterium tuberculosis/immunology , Transcription Factors/immunology , Tuberculosis/blood , Tuberculosis/immunology , Antibodies, Bacterial/blood , Bacterial Proteins/genetics , Bacterial Proteins/immunology , Bacterial Proteins/isolation & purification , Blotting, Western , Electrochemical Techniques , Enzyme-Linked Immunosorbent Assay , Humans , Mycobacterium tuberculosis/chemistry , Recombinant Proteins/genetics , Recombinant Proteins/immunology , Recombinant Proteins/isolation & purification , Transcription Factors/genetics , Transcription Factors/isolation & purification , Tuberculosis/diagnosis , Tuberculosis/microbiology
14.
PLoS One ; 7(8): e44172, 2012.
Article in English | MEDLINE | ID: mdl-22952917

ABSTRACT

BACKGROUND AND AIMS: Anti-sperm antibodies in can markedly reduce the likelihood of natural conception. The etiology of this anti-sperm immunity in human females is unknown. We compared the cytokine response of peripheral blood mononuclear cells (PBMCs) from infertile patients with or without anti-sperm antibodies (ASA) and fertile women. METHODOLOGY/PRINCIPAL FINDINGS: We cultivated the PBMCs together with sperm antigens (whole cells or cell lysate), and screened the supernatants for 40 cytokines by antibody array. When stimulated with whole sperm cells, the PBMCs from patients with ASA produce less IL-3, IL-11, IL-13, ICAM-1, GCSF and more IL-2, IL-4 and IL-12p70 as compared to healthy women. PBMCs from patients with ASA produce typically less IL-13, IL-7, IL-17 and MIG, and more MIP-1ß and IL-8, as compared to PBMCs from patients without ASA. In response to sperm cell lysate, PBMCs from infertile women without ASA respond initially by increase in production of growth factors (GCSF, GM-CSF and PDGF-BB) followed by increase in chemokines (e.g. IL-8, MCP-1 and MIP-1ß). CONCLUSIONS: Cellular immune responses to sperm antigens, measured by production of cytokines, differ among infertile women with ASA, infertile women without ASA and healthy women. This difference could play an important role in the initial steps of the infertility pathogenesis.


Subject(s)
Antibodies/blood , Antibodies/immunology , Cytokines/metabolism , Infertility, Female/blood , Infertility, Female/immunology , Leukocytes, Mononuclear/metabolism , Spermatozoa/immunology , Adult , Cell Extracts , Female , Fertility/immunology , Humans , Immune Sera/blood , Immune Sera/immunology , Male
15.
Bioconjug Chem ; 23(8): 1513-23, 2012 Aug 15.
Article in English | MEDLINE | ID: mdl-22812418

ABSTRACT

The development of vaccines against specific types of cancers will offer new modalities for therapeutic intervention. Here, we describe the synthesis of a novel vaccine construction prepared from spherical gold nanoparticles of 3-5 nm core diameters. The particles were coated with both the tumor-associated glycopeptides antigens containing the cell-surface mucin MUC4 with Thomsen Friedenreich (TF) antigen attached at different sites and a 28-residue peptide from the complement derived protein C3d to act as a B-cell activating "molecular adjuvant". The synthesis entailed solid-phase glycopeptide synthesis, design of appropriate linkers, and attachment chemistry of the various molecules to the particles. Attachment to the gold surface was mediated by a novel thiol-containing 33 atom linker which was further modified to be included as a third "spacer" component in the synthesis of several three-component vaccine platforms. Groups of mice were vaccinated either with one of the nanoplatform constructs or with control particles without antigen coating. Evaluation of sera from the immunized animals in enzyme immunoassays (EIA) against each glycopeptide antigen showed a small but statistically significant immune response with production of both IgM and IgG isotypes. Vaccines with one carbohydrate antigen (B, C, and E) gave more robust responses than the one with two contiguous disaccharides (D), and vaccine E with a TF antigen attached to threonine at the 10th position of the peptide was selected for IgG over IgM suggesting isotype switching. The data suggested that this platform may be a viable delivery system for tumor-associated glycopeptide antigens.


Subject(s)
Antigens, Tumor-Associated, Carbohydrate/chemistry , Cancer Vaccines/chemistry , Drug Design , Glycopeptides/chemistry , Gold/chemistry , Metal Nanoparticles , Prostatic Neoplasms/immunology , Amino Acid Sequence , Animals , Antigens, Tumor-Associated, Carbohydrate/immunology , Antigens, Tumor-Associated, Carbohydrate/metabolism , Cancer Vaccines/immunology , Cancer Vaccines/metabolism , Chemistry Techniques, Synthetic , Female , Glycopeptides/immunology , Glycopeptides/metabolism , Humans , Immune Sera/blood , Immune Sera/immunology , Ligands , Male , Mice , Molecular Sequence Data , Mucin-4/chemistry
16.
Mol Biol Rep ; 39(10): 9817-26, 2012 Oct.
Article in English | MEDLINE | ID: mdl-22729885

ABSTRACT

Aminopeptidases serve vital roles in metabolism of hormones, neurotransmission, turnover of proteins and immunological regulations. Leucine aminopeptidases catalyze the hydrolysis of amino-acid residues from the N-terminus of proteins and peptides. In the present study, leucine aminopeptidase 2 (LAP2) gene of Clonorchis sinensis (C. sinensis) was isolated and identified from an adult cDNA library of C. sinensis. Recombinant CsLAP2 was expressed and purified in Escherichia coli BL21. The open reading frame of LAP2 contains 1,560 bp equivalent to 519 amino acids, a similarity analysis showed a relatively low homology with Homo sapiens (19.0 %), Trypanosoma cruzi (18.0 %), Mus musculus (19.3 %), and relatively high homology with Schistosoma mansoni (65.6 %). The optimum condition of rCsLAP2 enzyme activity was investigated using a fluorescent substrate of Leu-MCA at 37 °C and pH 7.5. The K (m) and V (max) values of rCsLAP2 were 18.2 µM and 10.7 µM/min, respectively. CsLAP2 gene expression can be detected at the stages of the adult worm, metacercaria, excysted metacercaria and egg of C. sinensis using real-time PCR, no difference was observed at the stages of the adult worm, metacercaria and egg. However, CsLAP2 showed a higher expression level at the stage of excysted metacercaria than the adult worm (3.90-fold), metacercaria (4.60-fold) and egg (4.59-fold). Histochemistry analysis showed that CsLAP2 was located at the tegument and excretory vesicle of metacercaria, and the tegument and intestine of adult worm. The immune response specific to rCsLAP2 was characterized by a mixed response patterns of Th1 and Th2, indicating a compounded humoral and cellular immune response. The combined results from the present study indicate that CsLAP2 was an important antigen exposed to host immune system, and probably implicated as potential role in interaction with host cells in clonorchiasis.


Subject(s)
Clonorchis sinensis/enzymology , Helminth Proteins/immunology , Leucyl Aminopeptidase/immunology , Metacercariae/enzymology , Amino Acid Sequence , Animals , Antibodies, Helminth/blood , Antibodies, Helminth/chemistry , Blotting, Western , Cloning, Molecular , Clonorchiasis/immunology , Clonorchiasis/prevention & control , Clonorchis sinensis/immunology , Clonorchis sinensis/physiology , Conserved Sequence , Helminth Proteins/biosynthesis , Helminth Proteins/chemistry , Helminth Proteins/genetics , Immune Sera/blood , Immune Sera/chemistry , Immunoglobulin G/blood , Immunoglobulin G/chemistry , Immunotherapy, Active , Leucyl Aminopeptidase/biosynthesis , Leucyl Aminopeptidase/chemistry , Leucyl Aminopeptidase/genetics , Magnesium/chemistry , Male , Manganese/chemistry , Metacercariae/immunology , Metacercariae/physiology , Molecular Sequence Data , Phylogeny , Protein Transport , Rats , Rats, Sprague-Dawley , Recombinant Proteins/biosynthesis , Recombinant Proteins/chemistry , Recombinant Proteins/genetics , Recombinant Proteins/immunology , Sequence Analysis, DNA
17.
Br Poult Sci ; 52(5): 625-31, 2011 Oct.
Article in English | MEDLINE | ID: mdl-22029790

ABSTRACT

This research was conducted to determine the impact of diet supplementation with yeast cell walls and Yucca schidigera extract on the growth performance, antibody titres, and intestinal tissue histology of layer chicks. White, 1-d-old, Hy-Line hybrid chicks (n = 840) were divided into 4 main groups, each comprising 7 replicates of 30 chicks (n = 210): (1) control; (2) 1000 mg/kg yeast cell walls (YCW) added; (3) 1000 mg/kg Yucca schidigera extract (YE) added; and (4) 500 mg/kg YE + 500 mg/kg YCW added. The trial lasted 60 d. Daily weight gain of the chicks was positively affected between d 45-60 in the YE and YCW + YE groups compared with the control group. Overall, feed consumption did not differ between the control and YCW, YE, YCW + YE groups during the 60 d study period. Feed efficiency was better in the YE and YCW + YE groups than in the control group between d 1-60. During the 60 d evaluation period, live weight gain, and final live weight were higher in YE and YCW + YE groups than in the control group. Antibody titres against infectious bronchitis and infectious bursal disease did not differ among the 4 treatments, but those for Newcastle disease were higher in the YE + YCW groups than in the control, YCW and YE groups on d 45. There were differences in intestinal histomorphometry between the 4 treatments. The height of the jejunal and ileal villi was greater in the YE and YCW + YE groups than in the control and YCW groups. It can be concluded that YCW and YE supplementation for layer chicks is beneficial for growth performance and intestinal histology during the 1-60 d growing period.


Subject(s)
Cell Extracts/pharmacology , Cell Wall , Chickens/growth & development , Plant Extracts/pharmacology , Saccharomyces cerevisiae , Yucca , Animal Feed , Animals , Body Weight , Chickens/anatomy & histology , Chickens/immunology , Chickens/physiology , Diet/veterinary , Dietary Supplements , Digestion , Female , Ileum/anatomy & histology , Ileum/drug effects , Ileum/microbiology , Immune Sera/blood , Intestinal Mucosa/anatomy & histology , Intestinal Mucosa/drug effects , Intestinal Mucosa/microbiology , Jejunum/anatomy & histology , Jejunum/drug effects , Jejunum/microbiology , Weight Gain
18.
Nature ; 477(7365): 466-70, 2011 Sep 22.
Article in English | MEDLINE | ID: mdl-21849977

ABSTRACT

Broadly neutralizing antibodies against highly variable viral pathogens are much sought after to treat or protect against global circulating viruses. Here we probed the neutralizing antibody repertoires of four human immunodeficiency virus (HIV)-infected donors with remarkably broad and potent neutralizing responses and rescued 17 new monoclonal antibodies that neutralize broadly across clades. Many of the new monoclonal antibodies are almost tenfold more potent than the recently described PG9, PG16 and VRC01 broadly neutralizing monoclonal antibodies and 100-fold more potent than the original prototype HIV broadly neutralizing monoclonal antibodies. The monoclonal antibodies largely recapitulate the neutralization breadth found in the corresponding donor serum and many recognize novel epitopes on envelope (Env) glycoprotein gp120, illuminating new targets for vaccine design. Analysis of neutralization by the full complement of anti-HIV broadly neutralizing monoclonal antibodies now available reveals that certain combinations of antibodies should offer markedly more favourable coverage of the enormous diversity of global circulating viruses than others and these combinations might be sought in active or passive immunization regimes. Overall, the isolation of multiple HIV broadly neutralizing monoclonal antibodies from several donors that, in aggregate, provide broad coverage at low concentrations is a highly positive indicator for the eventual design of an effective antibody-based HIV vaccine.


Subject(s)
Antibodies, Neutralizing/immunology , HIV Antibodies/immunology , HIV/classification , HIV/immunology , AIDS Vaccines/biosynthesis , AIDS Vaccines/immunology , Antibodies, Monoclonal/immunology , Cell Line , Epitope Mapping , Epitopes/chemistry , Epitopes/immunology , Glycoproteins/chemistry , Glycoproteins/immunology , Glycosylation , HEK293 Cells , HIV/isolation & purification , HIV Infections/immunology , HIV Infections/therapy , Human Immunodeficiency Virus Proteins/chemistry , Human Immunodeficiency Virus Proteins/immunology , Humans , Immune Sera/blood , Immune Sera/immunology , Molecular Sequence Data , Neutralization Tests
19.
Rev Sci Tech ; 30(3): 809-19, 2011 Dec.
Article in English | MEDLINE | ID: mdl-22435193

ABSTRACT

The World Organisation for Animal Health (OIE) requested an International Standard anti-Brucella melitensis Serum (ISaBmS) to standardise diagnostic tests and reagents for sheep and goats. The agreed criteria were the highest dilution (in negative serum) of the standard which must give a positive result and the lowest dilution (in negative serum) which must simultaneously give a negative result. The two dilutions for each assay were, respectively: indirect enzyme-linked immunosorbent assay (iELISA) 1/64 and 1/750, competitive ELISA (cELISA) 1/8 and 1/300, fluorescent polarisation assay (FPA) 1/16 and 1/200, Rose Bengal test (RBT) 1/16 and 1/200. The OIE International Standard Serum (OIEISS) will remain the primary standard for the RBT; the ISaBmS is an additional standard. It was impossible to set criteria for the complement fixation test, therefore the OIEISS will remain the primary standard. The ISaBmS can be used to standardise iELISA, cELISA and FPA to diagnose sheep and goat brucellosis. This standard should facilitate harmonisation of tests used for brucellosis surveillance and international trade in these species.


Subject(s)
Antibodies, Bacterial/blood , Brucella melitensis/immunology , Brucellosis/veterinary , Goat Diseases/diagnosis , Immune Sera/blood , Analysis of Variance , Animals , Brucellosis/diagnosis , Complement Fixation Tests/veterinary , Dose-Response Relationship, Drug , Enzyme-Linked Immunosorbent Assay/veterinary , Female , Fluorescence Polarization Immunoassay/veterinary , Goats , Pregnancy , Reference Standards , Sheep , Sheep Diseases/diagnosis
20.
Br Poult Sci ; 51(6): 805-10, 2010 Dec.
Article in English | MEDLINE | ID: mdl-21161788

ABSTRACT

1. This research was conducted to determine the effect of diet supplementation with Echinacea extract (cichoric acid) on the growth performance, antibody titres and intestinal tissue histology of layer chicks. 2. White, 1-d-old, Hy-Line hybrid chicks (n = 540) were divided into three treatments, each consisting of 6 groups of 30 chicks (n = 180): (1) control; (2) 2·5 mg/kg cichoric-acid-fed; and (3) 5 mg/kg cichoric-acid-fed. The trial lasted 60 d. 3. While the growth performance of the chicks was depressed between d 1 and 45, it was found to improve between d 45 and 60. 4. Feed consumption was lower in both of the cichoric-acid-fed groups than in the control group between d 1-15 and 15-30, but was higher between d 30 and 45. Overall, mean feed consumption did not differ between the control and cichoric-acid-fed groups during the 60 d study period. 5. During the 60 d evaluation period, live weight gain, feed utilisation rate and final live weight were higher in the control group than in both of the cichoric-acid-fed groups. 6. Antibody titres against infectious bronchitis and infectious bursal disease did not differ between the three groups, but those for Newcastle disease were higher in the 2·5 mg/kg cichoric-acid-fed group than in the control group after 45 d. 7. Height and width of the jejunal villus and the thickness of the muscle layer were lower in the 5 mg/kg cichoric-acid-fed group than in both the control and the 2·5 mg/kg cichoric-acid-fed groups. The height of the ileal villus was also lower in the 5 mg/kg cichoric-acid-fed group than in the other two groups. 8. Echinacea extract supplementation for layer chicks appears not to benefit growth performance and intestinal histology during the growing period.


Subject(s)
Chickens/physiology , Echinacea , Intestines/anatomy & histology , Plant Extracts/pharmacology , Animals , Body Weight/drug effects , Bronchitis/immunology , Bronchitis/prevention & control , Bronchitis/veterinary , Chickens/immunology , Chickens/microbiology , Eating/drug effects , Feeding Behavior/drug effects , Female , Immune Sera/blood , Intestines/drug effects , Intestines/microbiology , Poultry Diseases/immunology , Poultry Diseases/microbiology , Poultry Diseases/prevention & control
SELECTION OF CITATIONS
SEARCH DETAIL